After 2 years of follow up, invasive disease-free survival was 94.2% in patients treated with neratinib compared with 91.9% in those who received placebo.
Natiijooyinka tijaabada ExteNET waxay muujiyeen in ka dib laba sano oo dabagal ah, badbaadin aan cudur lahayn (iDFS) ay ahayd 94.2% maadooyinka lagu daaweeyay neratinib marka la barbar dhigo 91.9% kuwa hela placebo.